Off-Label Compendia Weaknesses Illustrated By Tarceva Evidence Gaps
Compendia are often critical to reimbursement for oncology sponsors, but University of North Carolina researchers argue in JAMA the system needs to be revamped.
You may also be interested in...
‘Episode of care’ payment model could reduce off-label cancer drug prescribing but also offers an opportunity for increased use of high-value drugs, including those that can reduce costs by decreasing hospitalizations, University of Chicago’s Rena Conti suggests.
After years of industry prodding, FDA schedules a two-day public meeting in November to establish direction for off-label regulation, but the agency is already being pulled in multiple directions.
Richard Pazdur is stepping aside from FDA's Office of Hematology and Oncology Products to head the agency's newly created Oncology Center of Excellence, but he expects to still run twice-weekly group meetings at OHOP.